Clinical actionability of molecular targets in endometrial cancer
Postagens
Multiomics Profiling Establishes the Polypharmacologyof FDA-Approved CDK4/6 Inhibitors and the Potentialfor Differential Clinical Activity
https://www.sciencedirect.com/science/article/pii/S2451945619301746
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
https://www.nature.com/articles/s41523-019-0121-y.pdf